Literature DB >> 16627578

Mineralocorticoid receptor blockade but not steroid withdrawal reverses renal fibrosis in deoxycorticosterone/salt rats.

Emily Y M Lam1, John W Funder, David J Nikolic-Paterson, Peter J Fuller, Morag J Young.   

Abstract

The pathophysiologic effects of nonepithelial mineralocorticoid receptor (MR) activation include vascular inflammation followed by renal and cardiac remodeling in experimental animals. We have recently shown that MR blockade can reverse established cardiac fibrosis and vascular inflammation; the present study explores whether a similar protection is seen in renal tissue. Rats were uninephrectomized and maintained on 0.9% NaCl solution to drink and treated as follows: control, vehicle; deoxycorticosterone (DOC), 20 mg/wk sc for 4 wk and then killed; DOC for 8 wk; DOC for 4 wk and no steroid for wk 5-8; DOC for 8 wk and eplerenone 100 mg/kg.d in the food for wk 5-8. DOC increased renal collagen at 4 and 8 wk; rats given DOC for 4 wk and killed at 8 wk showed levels of fibrosis identical with those killed at 4 wk, whereas rats given DOC for 8 wk plus eplerenone for wk 5-8 were indistinguishable from control. The inflammatory markers ED-1, osteopontin, and cyclooxygenase-2 remained significantly elevated despite the withdrawal of DOC (DOC404), whereas eplerenone restored cyclooxygenase-2 expression (but not that of ED-1 or osteopontin) to control levels. In addition, markers of oxidative stress and TGFbeta were determined. We hypothesize that continuing tubular inflammation and fibrosis despite DOC withdrawal indicates that the renal tissue may reflect MR activation in the context of tissue damage.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16627578     DOI: 10.1210/en.2005-1527

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  13 in total

1.  Protective effects of eplerenone on podocyte injury in adriamycin nephropathy rats.

Authors:  Zhan Fang; Chun Zhang; Fangfang He; Shan Chen; Xifeng Sun; Zhonghua Zhu; Jianshe Liu; Xianfang Meng
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-06-14

Review 2.  The multifaceted mineralocorticoid receptor.

Authors:  Elise Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Compr Physiol       Date:  2014-07       Impact factor: 9.090

Review 3.  Aldosterone-induced fibrosis in the kidney: questions and controversies.

Authors:  Andrew S Brem; David J Morris; Rujun Gong
Journal:  Am J Kidney Dis       Date:  2011-06-25       Impact factor: 8.860

4.  Myeloid cells are capable of synthesizing aldosterone to exacerbate damage in muscular dystrophy.

Authors:  Jessica A Chadwick; Sarah A Swager; Jeovanna Lowe; Steven S Welc; James G Tidball; Celso E Gomez-Sanchez; Elise P Gomez-Sanchez; Jill A Rafael-Fortney
Journal:  Hum Mol Genet       Date:  2016-12-01       Impact factor: 6.150

Review 5.  Role of mineralocorticoid action in the brain in salt-sensitive hypertension.

Authors:  Kenji Oki; Elise P Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Clin Exp Pharmacol Physiol       Date:  2012-01       Impact factor: 2.557

6.  Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice.

Authors:  Michael G Usher; Sheng Zhong Duan; Christine Y Ivaschenko; Ryan A Frieler; Stefan Berger; Günther Schütz; Carey N Lumeng; Richard M Mortensen
Journal:  J Clin Invest       Date:  2010-08-09       Impact factor: 14.808

Review 7.  Therapeutic targeting of aldosterone: a novel approach to the treatment of glomerular disease.

Authors:  Andrew S Brem; Rujun Gong
Journal:  Clin Sci (Lond)       Date:  2015-05       Impact factor: 6.124

8.  Actions of aldosterone in the cardiovascular system: the good, the bad, and the ugly?

Authors:  Michael Gekle; Claudia Grossmann
Journal:  Pflugers Arch       Date:  2008-11-19       Impact factor: 3.657

9.  Inflammatory monocyte/macrophage modulation by liposome-entrapped spironolactone ameliorates acute lung injury in mice.

Authors:  Wen-Jie Ji; Yong-Qiang Ma; Xin Zhang; Li Zhang; Yi-Dan Zhang; Cheng-Cheng Su; Guo-An Xiang; Mei-Ping Zhang; Zhi-Chun Lin; Lu-Qing Wei; Peizhong P Wang; Zhuoli Zhang; Yu-Ming Li; Xin Zhou
Journal:  Nanomedicine (Lond)       Date:  2016-05-12       Impact factor: 5.307

10.  The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism.

Authors:  Rena J Eudy; Vaishali Sahasrabudhe; Kevin Sweeney; Meera Tugnait; Amanda King-Ahmad; Kristen Near; Paula Loria; Mary Ellen Banker; David W Piotrowski; Carine M Boustany-Kari
Journal:  J Transl Med       Date:  2011-10-21       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.